Biotech company Noxopharm (ASX:NOX) secured AU$1.8 million in advanced funding from Endpoints Capital against its Australian Government research and development tax incentive scheme rebate for the fiscal year 2023-2024, according to a Friday filing with the Australian Securities Exchange.
The company received the funding through a secured loan agreement over the rebate at an annual interest rate of 15.80%. The loan is repayable from R&D rebate proceeds, estimated to be around AU$2.3 million for the year ending June 30, the filing said.
Price (AUD): $0.13, Change: $+0.010, Percent Change: +8.70%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。